199 Bay St, Suite 5300, Commerce Court West, Toronto, ON
Year called to bar: 2002 (ON); 2001 (NY)
Sara Zborovski is a partner in the Corporate Group. Her practice focuses on providing regulatory and commercial counsel to companies regulated by Health Canada. She helps clients to navigate the regulatory landscape implemented by the Food and Drugs Act, the Cannabis Act and other legislation and associated regulations overseen by Health Canada and provincial regulators. Sara provides strategic counsel to pharmaceutical, cannabis, food and beverage, natural health product, medical device, cosmetic and tobacco companies on market access, authorizations and licensing, advertising and marketing and product safety and recalls. Sara assists with product licence and market access strategies, establishment/facility licensing and GMP/GPP programs. On the compliance side, she assists clients in developing SOPs and compliance policies, reviews product packaging and labelling and provides strategic advice on advertising and marketing programs, including assistance with pre-clearance agencies and representation before the Pharmaceutical Advertising Advisory Board and Advertising Standards Canada. Sara also advises clients on federal and provincial privacy laws, particularly as these relate to healthcare, and federal and provincial access to information and freedom of information matters.
On March 23, 2018, Aphria Inc. (Aphria)(TSX: APH and US OTC: APHQF) completed its acquisition of Nuuvera Inc. (Nuuvera) pursuant to a plan of arrangement under the Business Corporations Act (Ontario) for approximately $425 million.